STAGEZERO LIFE SCIENCES LTD (SZLS.CA) Fundamental Analysis & Valuation

TSX:SZLS • CA8525403017

Current stock price

0.04 CAD
0 (0%)
Last:

This SZLS.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. SZLS.CA Profitability Analysis

1.1 Basic Checks

  • SZLS had negative earnings in the past year.
  • SZLS had a negative operating cash flow in the past year.
SZLS.CA Yearly Net Income VS EBIT VS OCF VS FCFSZLS.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 -2M -4M -6M -8M -10M

1.2 Ratios

  • SZLS has a Return On Assets of -2456.86%. This is amonst the worse of the industry: SZLS underperforms 95.83% of its industry peers.
Industry RankSector Rank
ROA -2456.86%
ROE N/A
ROIC N/A
ROA(3y)-594.09%
ROA(5y)-442.86%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SZLS.CA Yearly ROA, ROE, ROICSZLS.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 0 500 -500 -1K -1.5K

1.3 Margins

  • SZLS has a better Gross Margin (0.33%) than 62.50% of its industry peers.
  • The Profit Margin and Operating Margin are not available for SZLS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 0.33%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SZLS.CA Yearly Profit, Operating, Gross MarginsSZLS.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 0 -1K -2K -3K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. SZLS.CA Health Analysis

2.1 Basic Checks

  • SZLS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • SZLS has more shares outstanding than it did 1 year ago.
  • Compared to 1 year ago, SZLS has a worse debt to assets ratio.
SZLS.CA Yearly Shares OutstandingSZLS.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M
SZLS.CA Yearly Total Debt VS Total AssetsSZLS.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2M 4M 6M 8M 10M

2.2 Solvency

  • SZLS has an Altman-Z score of -390.01. This is a bad value and indicates that SZLS is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of SZLS (-390.01) is worse than 95.83% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -390.01
ROIC/WACCN/A
WACC6.71%
SZLS.CA Yearly LT Debt VS Equity VS FCFSZLS.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 2M -2M -4M -6M -8M

2.3 Liquidity

  • A Current Ratio of 0.04 indicates that SZLS may have some problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 0.04, SZLS is doing worse than 91.67% of the companies in the same industry.
  • SZLS has a Quick Ratio of 0.04. This is a bad value and indicates that SZLS is not financially healthy enough and could expect problems in meeting its short term obligations.
  • SZLS has a worse Quick ratio (0.03) than 91.67% of its industry peers.
Industry RankSector Rank
Current Ratio 0.04
Quick Ratio 0.03
SZLS.CA Yearly Current Assets VS Current LiabilitesSZLS.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2M 4M 6M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. SZLS.CA Growth Analysis

3.1 Past

  • The earnings per share for SZLS have decreased strongly by -140.00% in the last year.
  • SZLS shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -35.06%.
  • Measured over the past years, SZLS shows a very strong growth in Revenue. The Revenue has been growing by 56.10% on average per year.
EPS 1Y (TTM)-140%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)-35.06%
Revenue growth 3Y200.53%
Revenue growth 5Y56.1%
Sales Q2Q%-6.25%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SZLS.CA Yearly Revenue VS EstimatesSZLS.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 1M 2M 3M 4M 5M
SZLS.CA Yearly EPS VS EstimatesSZLS.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 -0.05 -0.1 -0.15 -0.2

More info and screens

Find the best growth stocksShow best growing peers

0

4. SZLS.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for SZLS. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SZLS.CA Price Earnings VS Forward Price EarningsSZLS.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SZLS.CA Per share dataSZLS.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.05 -0.1 -0.15

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SZLS.CA Dividend Analysis

5.1 Amount

  • No dividends for SZLS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

SZLS.CA Fundamentals: All Metrics, Ratios and Statistics

STAGEZERO LIFE SCIENCES LTD

TSX:SZLS (4/8/2024, 7:00:00 PM)

0.04

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A
Earnings (Next)N/A
Inst Owners0.18%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap4.92M
Revenue(TTM)3.00M
Net Income(TTM)-12.53M
Analysts42.22
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.19
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.17
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS0.03
BVpS-0.1
TBVpS-0.1
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -2456.86%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 0.33%
FCFM N/A
ROA(3y)-594.09%
ROA(5y)-442.86%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover5.88
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.04
Quick Ratio 0.03
Altman-Z -390.01
F-Score3
WACC6.71%
ROIC/WACCN/A
Cap/Depr(3y)25.1%
Cap/Depr(5y)18.06%
Cap/Sales(3y)1.55%
Cap/Sales(5y)7.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-140%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-35.06%
Revenue growth 3Y200.53%
Revenue growth 5Y56.1%
Sales Q2Q%-6.25%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y47.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y87.22%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y86.81%
OCF growth 3YN/A
OCF growth 5YN/A

STAGEZERO LIFE SCIENCES LTD / SZLS.CA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of STAGEZERO LIFE SCIENCES LTD (SZLS.CA) stock?

ChartMill assigns a fundamental rating of 1 / 10 to SZLS.CA.


What is the valuation status for SZLS stock?

ChartMill assigns a valuation rating of 0 / 10 to STAGEZERO LIFE SCIENCES LTD (SZLS.CA). This can be considered as Overvalued.


What is the profitability of SZLS stock?

STAGEZERO LIFE SCIENCES LTD (SZLS.CA) has a profitability rating of 1 / 10.


Can you provide the financial health for SZLS stock?

The financial health rating of STAGEZERO LIFE SCIENCES LTD (SZLS.CA) is 0 / 10.